{"entity":{"id":"nct05744427","kind":"trial","name":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of JSKN003 in advanced solid tumours, run by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, active and no longer recruiting.","summary":"Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05744427 by Jiangsu Alphamab Biopharmaceuticals Co., Ltd, with 725 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2026-07-30. Interventions recorded: JSKN003.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05744427","url":"https://clinicaltrials.gov/study/NCT05744427"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["jskn003"],"companies":["alphamab"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05744427","phase":"1/2","setting":"Phase I/II Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of JSKN003 in Chinese Subjects With Advanced Solid Tumors","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","enrolled":725,"outcomes":[]},"route":"/trials/nct05744427/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"jskn003","kind":"drug","name":"JSKN003","route":"/drugs/jskn003/"}],"company":[{"id":"alphamab","kind":"company","name":"Alphamab Oncology","route":"/companies/alphamab/"}]}}